Eqvista vs Vestd
Compare with for .
Eqvista is the better fit.
It publishes its prices; the other needs a sales quote.
How we work out the matchFine-tune
What you'd pay
Entry plan for 10 people, billed yearly where offered. Prices checked Oct 2026.
No public price
Eqvista
Budget-conscious US startups that mainly need a compliant 409A valuation and a clean cap table.
Vestd
UK companies setting up or running an EMI or growth share scheme that want guided, human support.
Side by side
| Eqvista | Vestd | |
|---|---|---|
| Pricing | Free under 20 stakeholders; Premium $2/stakeholder/month | From £25/month (Essentials); Starter from £220/month |
| G2 Rating | Not yet verified | 4.7 (63 reviews) |
| Best For | Budget-conscious US startups that mainly need a compliant 409A valuation and a clean cap table. | UK companies setting up or running an EMI or growth share scheme that want guided, human support. |
Pros and cons
Eqvista
Pros
- Low entry price for cap table and 409A
- Waterfall modeling without a top-tier plan
- ASC 718 available as a service from $500
- Unlimited 409A updates within the bundle
Cons
- US-focused, with no UK EMI features on its pricing page
- Lighter HRIS automation and investor tools than Carta or Ledgy
- Custom pricing above 50 stakeholders
Vestd
Pros
- Built for UK share schemes and HMRC workflows
- Unlimited HMRC valuations on Guided
- Specialist support for scheme design
- Low-cost Essentials plan before you need a scheme
Cons
- No free plan and a 12-month minimum term
- EMI requires the Guided plan (from £420/month)
- Poor fit for US C-corps
Related comparisons
Best Cap Table Software
Carta is the best cap table software for most startups: free up to 25 stakeholders and $1M raised, and it scales to 409As and ASC 718. Pick Cake Equity if you want published prices.
Carta alternatives
Pick Cake Equity if you are a US startup leaving Carta over price: published plans, free migration and two 409As a year on Team. Pick Ledgy if you are in the UK or Europe. Stay on Carta if you want one vendor for everything up to IPO.